← Leaderboards
Wei Li
University Of Tennessee Health Sci Ctr
$11,377,399
Attributed
$18,666,379
Total exposure
16
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2008–25$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,666,379 · 16
By mechanism
R01$13,020,294 · 6
RF1$2,157,183 · 1
R41$829,913 · 2
R61$765,000 · 1
S10$577,900 · 2
R43$399,964 · 1
Top collaborators
- Duane D Miller12 shared
- Muxiang Zhou5 shared
- Jianxiong Jiang3 shared
- Tiffany Nicole Seagroves3 shared
- Kiran Bhaskar2 shared
- Francesca-Fang Liao2 shared
- Wei Wang1 shared
- Zhongzhi Wu1 shared
Most similar at University Of Tennessee Health Sci Ctr
Same institution · by research overlap
- Duane D Miller$5,855,110
Others in their field
Top investigators on “Toxic Effect”
- George R Seage · Abt Associates, Inc.$224,114,540
- Peter C Adamson · National Childhood Cancer Foundation$126,756,857
- Gregory H Reaman · National Childhood Cancer Foundation$123,836,183
- Carol Nesel · Westat$116,355,411
- Mary M Horowitz · Medical College Of Wisconsin$90,165,506
- Barney Sparrow · Battelle Memorial Institute$88,494,220
Research focus
Toxic EffectIn VivoAnalogPharmaceutical PreparationsStructureScaffoldPropertyDrug KineticsDesignBindingDrug ResistanceRoentgen RaysCell LineNovel TherapeuticsNeoplasm MetastasisTumorCancer TypeCancer CellIn VitroBaseTargeted TreatmentApoptosisMalignant NeoplasmsInhibitor
Grant awards (42)
Validation of a novel tau clearance mechanism.$688,273
R01 · FY2025 · AG
Targeted MDM2 degradation for improved treatment for triple-negative breast cancer$658,561
R01 · FY2025 · CA · contact PI
Targeting brain and bone metastases in metastatic breast cancer for improved patient survival$614,894
R01 · FY2025 · CA · contact PI
Development of a potent and highly brain-penetrable antimitotic agent SEAK193 to treat breast cancer brain metastasis$399,981
R41 · FY2025 · CA · contact PI
Targeting the colchicine binding site in tubulin for cancer therapy$389,817
R01 · FY2025 · CA · contact PI
Targeting TRPC3 Channels for Epileptic Seizures$346,500
R33 · FY2025 · NS
Targeting brain and bone metastases in metastatic breast cancer for improved patient survival$584,152
R01 · FY2024 · CA · contact PI
Dual inhibition of MDM2 and XIAP as a therapeutic strategy in cancer$514,428
R01 · FY2024 · CA · contact PI
Targeting the colchicine binding site in tubulin for cancer therapy$370,326
R01 · FY2024 · CA · contact PI
Targeting brain and bone metastases in metastatic breast cancer for improved patient survival$614,894
R01 · FY2023 · CA · contact PI
Dual inhibition of MDM2 and XIAP as a therapeutic strategy in cancer$530,672
R01 · FY2023 · CA · contact PI
Developing a selective TRPC3 ion channel inhibitor for epilepsy treatment$429,932
R41 · FY2023 · NS · contact PI
Targeting the colchicine binding site in tubulin for cancer therapy$389,817
R01 · FY2023 · CA · contact PI
Targeting TRPC3 Channels for Epileptic Seizures$380,000
R61 · FY2023 · NS
Validation of a novel tau clearance mechanism.$2,157,183
RF1 · FY2022 · AG
Dual inhibition of MDM2 and XIAP as a therapeutic strategy in cancer$530,672
R01 · FY2022 · CA · contact PI
Targeting TRPC3 Channels for Epileptic Seizures$385,000
R61 · FY2022 · NS
Targeting the colchicine binding site in tubulin for cancer therapy$382,020
R01 · FY2022 · CA · contact PI
Dual inhibition of MDM2 and XIAP as a therapeutic strategy in cancer$541,500
R01 · FY2021 · CA · contact PI
Targeting the colchicine binding site in tubulin for cancer therapy$403,307
R01 · FY2021 · CA · contact PI
Dual inhibition of MDM2 and XIAP as a therapeutic strategy in cancer$554,502
R01 · FY2020 · CA · contact PI
Feasibility study of developing SEAK-114 for the treatment of pediatric cancers$399,964
R43 · FY2020 · CA
Selective Targeting Survivin for Cancer Therapy$380,127
R01 · FY2020 · CA · contact PI
Targeting the colchicine site in tubulin for advanced melanoma$365,493
R01 · FY2020 · CA · contact PI
Selective Targeting Survivin for Cancer Therapy$368,723
R01 · FY2019 · CA · contact PI
Targeting the colchicine site in tubulin for advanced melanoma$354,527
R01 · FY2019 · CA · contact PI
Selective Targeting Survivin for Cancer Therapy$380,127
R01 · FY2018 · CA · contact PI
Targeting the colchicine site in tubulin for advanced melanoma$365,493
R01 · FY2018 · CA · contact PI
Selective Targeting Survivin for Cancer Therapy$380,127
R01 · FY2017 · CA · contact PI
Targeting the colchicine site in tubulin for advanced melanoma$365,493
R01 · FY2017 · CA · contact PI
Selective Targeting Survivin for Cancer Therapy$393,127
R01 · FY2016 · CA · contact PI
Targeting the colchicine site in tubulin for advanced melanoma$391,361
R01 · FY2016 · CA · contact PI
Discovery of Novel Thiazole Analogs for Treating Malignant Melanoma$307,100
R01 · FY2015 · CA · contact PI
Discovery of Novel Thiazole Analogs for Treating Malignant Melanoma$297,887
R01 · FY2014 · CA · contact PI
Discovery of tissue-selective, nonhypercalcemic VDR modulators for RA treatment$191,250
R21 · FY2014 · AR · contact PI
Discovery of Novel Thiazole Analogs for Treating Malignant Melanoma$288,674
R01 · FY2013 · CA · contact PI
Discovery of tissue-selective, nonhypercalcemic VDR modulators for RA treatment$159,375
R21 · FY2013 · AR · contact PI
Acquisition of a Q-TOF Mass Spectrometer$325,000
S10 · FY2012 · OD · contact PI
Discovery of Novel Thiazole Analogs for Treating Malignant Melanoma$307,100
R01 · FY2012 · CA · contact PI
Discovery of Novel Thiazole Analogs for Treating Malignant Melanoma$307,100
R01 · FY2011 · CA · contact PI
Acquisition of a 400MHz Solution NMR System with an Autosampler$252,900
S10 · FY2010 · RR · contact PI
Discovery of Novel Cytotoxic Agents for Advanced Melanoma$219,000
R15 · FY2008 · CA · contact PI